Boston Scientific v. Cook
This article was originally published in The Gray Sheet
Executive Summary
Ruling on summary judgement motions is slated for June 6 in the firms' dispute over the license of paclitaxel-coating technology from Cook to Guidant for its Achieve drug-coated stent, according to Boston Scientific. No trial would be required for issues decided on summary judgement by the Northern Illinois federal court. Boston Scientific alleges that the licensing agreement violates a co-exclusive agreement for the technology reached with Canadian firm Angiotech Pharmaceuticals and Cook in 1997 (1"The Gray Sheet" July 14, 1997, I&W-1). The court has dismissed a Cook claim of unfair trade practices but declined to dismiss Cook's anti-trust claim, according to Boston Scientific. Guidant maintains that its agreement with Cook establishes a legal distributor relationship with the privately held firm...